Biopharmaceutical company GSK is growing its Massachusetts work force, announcing plans to move its vaccines research and development and infectious disease teams from suburban Maryland to Cambridge in 2026. The teams will move to 200 Cambridgepark Drive, an office and laboratory building where GSK leases about 200,000 square feet . GSK is still finalizing the number of employees who will be involved in the move, a spokesperson for the London-based company said, though GSK’s website says the Rockville, Md., site is home to 350 employees. Employees at 200 Cambridgepark focus on early drug discovery and immunology research, said the spokesperson, who added that the incoming teams will zero in on mRNA, structural biology, and viral vaccine research and development. “We believe the Greater Boston area is an important hub for the biotech and pharma industry, which is why we’ve invested in growing our footprint and expanding our R&D space in Cambridge, with a primary focus on additional state-of-the-art lab space,” said the GSK spokesperson. “Here, we will bring together talent and expertise, building upon GSK’s long history of vaccine development, to create globally leading viral capabilities and cutting-edge vaccines technologies, as we add to our robust portfolio targeting infectious diseases at every stage of life.” Beyond its 200 Cambridgepark facility, GSK has a significant footprint in Massachusetts, with two other research and development sites in Cambridge — right next to MIT in Technology Square, and on Binney Street in Kendall Square — as well as another location in Waltham. GSK’s website says it employs approximately 700 people in Greater Boston, out of roughly 15,000 workers nationwide. The vaccine research and development and infectious disease teams will continue to work at the Maryland facility until March 2026, with GSK’s lease there expiring shortly after, the spokesperson confirmed. GSK also has a manufacturing site in Maryland, where it will be staying. In 2023, GSK announced that it was expanding its lease at 200 Cambridgepark, which is managed by real estate investment management company King Street Properties. GSK already occupied upward of 40,000 square feet at the site, and signed on for an additional 155,000 square feet, meaning it occupies the vast majority of the building, which King Street Properties lists as totaling 222,000 square feet. GSK is the sole tenant of the building, the spokesperson said.
CONTINUE READING
